Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Principal Investigator
Jyoti Mayadev, MD
Status
Terminated
Date Opened To Accrual
October 26 2018
Date Closed to Accrual
June 11 2020
Date of Study Termination
September 12 2025
Disease Site
Gynecologic [GY]
Cervix
Phase
I
Developmental Therapeutics
No
Primary Objective
To determine whether differences in sequencing of atezolizumab and chemoradiation result in differential immune activation, as determined by clonal expansion of T cell receptor beta (TCRB) repertoires in peripheral blood on day 21.
Patient Population
Patients with locally advanced cervical cancer.
Target Accrual
40
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.